Linked Life Data

7532543

Source:http://linkedlifedata.com/resource/pubmed/id/7532543

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1995-3-30
pubmed:abstractText
Dendritic antigen-presenting cells are considered to be the most effective stimulators of T cell immunity. The use of dendritic cells has been proposed to generate therapeutic T cell responses to tumor antigens in cancer patients. One limitation is that the number of dendritic cells in peripheral blood is exceedingly low. Dendritic cells originate from CD34+ hematopoietic progenitor cells (HPC) which are present in the bone marrow and in small numbers in peripheral blood. CD34+ HPC can be mobilized into the peripheral blood by in vivo administration of granulocyte-colony-stimulating factor. The aim of the current study was to determine whether functional dendritic cells could be elicited and grown in vitro from CD34+ HPC derived from bone marrow or granulocyte-colony-stimulating factor-mobilized peripheral blood. Culture of CD34+ HPC with granulocyte-macrophage-colony-stimulating factor and tumor necrosis factor alpha yielded a heterogeneous cell population containing cells with typical dendritic morphology. Phenotypic studies demonstrated a loss of the CD34 molecule over 1 week and an increase in cells expressing surface markers associated with dendritic cells, CD1a, CD80 (B7/BB1), CD4, CD14, HLA-DR, and CD64 (Fc gamma RI). Function was validated in experiments showing that cultured cells could stimulate proliferation of allogeneic CD4+ and CD8+ T lymphocytes. Antigen-presenting capacity was further confirmed in experiments showing that cultured cells could effectively stimulate tetanus toxoid-specific responses and HER-2/neu peptide-specific responses. The derivation and expansion of dendritic cells from cultured bone marrow or granulocyte-colony-stimulating factor-mobilized CD34+ HPC may provide adequate numbers for testing of dendritic cells in clinical studies, such as vaccine and T cell therapy trials.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1099-104
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:7532543-Antigen Presentation, pubmed-meshheading:7532543-Antigens, CD, pubmed-meshheading:7532543-Antigens, CD34, pubmed-meshheading:7532543-Antigens, CD80, pubmed-meshheading:7532543-Bone Marrow, pubmed-meshheading:7532543-Bone Marrow Cells, pubmed-meshheading:7532543-Cells, Cultured, pubmed-meshheading:7532543-Dendritic Cells, pubmed-meshheading:7532543-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:7532543-Hematopoietic Stem Cells, pubmed-meshheading:7532543-Histocompatibility Antigens Class II, pubmed-meshheading:7532543-Humans, pubmed-meshheading:7532543-Leukocytes, Mononuclear, pubmed-meshheading:7532543-Lymphocyte Activation, pubmed-meshheading:7532543-Macrophages, pubmed-meshheading:7532543-Peptide Fragments, pubmed-meshheading:7532543-Phenotype, pubmed-meshheading:7532543-Receptor, erbB-2, pubmed-meshheading:7532543-Stimulation, Chemical, pubmed-meshheading:7532543-T-Lymphocytes, pubmed-meshheading:7532543-Tumor Necrosis Factor-alpha
pubmed:year
1995
pubmed:articleTitle
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood.
pubmed:affiliation
Department of Medicine, University of Washington, Seattle 98195.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't